Notice of Results
10 Octobre 2019 - 3:30PM
Summit Therapeutics plc (‘Summit’ or the
‘Company’)
Summit Therapeutics to Report Financial
Results for the Second Quarter and Half Year Ended 31 July 2019 on
11 October 2019
Oxford, UK, and Cambridge, MA, US, 10
October 2019 – Summit Therapeutics plc (NASDAQ: SMMT, AIM:
SUMM) a leader in new mechanism antibiotic innovation, will
announce its financial results for the second quarter and half year
ended 31 July 2019 on 11 October 2019.
Summit will host a conference call the same day
at 1:00pm BST / 8:00am EDT. Conference call information will be
included in the second quarter and half year results press release,
and a replay of the call will also be available through the
Company’s website, www.summitplc.com.
About Summit Therapeutics
Summit Therapeutics is a leader in antibiotic innovation. Our new
mechanism antibiotics are designed to become the new standards of
care for the benefit of patients and create value for payors and
healthcare providers. We are currently developing new mechanism
antibiotics for infections caused by C. difficile, N. gonorrhoeae
and Enterobacteriaceae and are using our proprietary Discuva
Platform to expand our pipeline. For more information, visit
www.summitplc.com and follow us on Twitter @summitplc.
Contacts
Summit |
|
|
Glyn Edwards / Richard Pye (UK office) |
Tel: |
44 (0)1235 443 951 |
Michelle Avery (US office) |
|
+1 617 225 4455 |
|
|
|
Cairn Financial Advisers LLP (Nominated
Adviser) |
Tel: |
+44 (0)20 7213 0880 |
Liam Murray / Tony Rawlinson |
|
|
|
|
|
N+1 Singer (Joint Broker) |
Tel: |
+44 (0)20 7496 3000 |
Aubrey Powell / Jen Boorer, Corporate FinanceTom Salvesen,
Corporate Broking |
|
|
|
|
|
Bryan Garnier & Co Limited (Joint Broker) |
Tel: |
+44 (0)20 7332 2500 |
Phil Walker / Dominic Wilson |
|
|
MSL Group (US) |
Tel: |
+1 781 684 6652 |
Erin Anthoine |
|
summit@mslgroup.com |
|
|
|
Consilium Strategic Communications (UK) |
Tel: |
+44 (0)20 3709 5700 |
Mary-Jane Elliott / Sue Stuart / Sukaina Virji |
|
summit@consilium-comms.com |
Lindsey Neville |
|
|
-END-
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Sept 2024 à Oct 2024
Summit Therapeutics (NASDAQ:SMMT)
Graphique Historique de l'Action
De Oct 2023 à Oct 2024